Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in Oncology

Journal Scan / Research · September 21, 2017

Lenalidomide Maintenance After First-Line Therapy for High-Risk Chronic Lymphocytic Leukemia

The Lancet Haematology

 

 Save  Recommend
 Share

Additional Info

The Lancet Haematology
Lenalidomide Maintenance After First-Line Therapy for High-Risk Chronic Lymphocytic Leukaemia (CLLM1): Final Results From a Randomised, Double-Blind, Phase 3 Study
Lancet Haematol 2017 Sep 12;[EPub Ahead of Print], AM Fink, J Bahlo, S Robrecht, O Al-Sawaf, A Aldaoud, H Hebart, K Jentsch-Ullrich, S Dörfel, K Fischer, CM Wendtner, T Nösslinger, P Ghia, F Bosch, AP Kater, H Döhner, M Kneba, KA Kreuzer, E Tausch, S Stilgenbauer, M Ritgen, S Böttcher, B Eichhorst, M Hallek

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated